ACXP - CIK 0001736243
The table below shows Acurx Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $341.47K | $429.69K | $524.21K | $598.80K | $1.20M | $1.83M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.37M |
| $1.60M |
| $1.75M |
| $1.58M |
| $1.63M |
| $2.30M |
| Operating income | -$1.72M | -$2.03M | -$2.27M | -$2.18M | -$2.83M | -$4.12M |
| Income tax | - | - | - | - | - | - |
| Net income | -$1.68M | -$1.99M | -$2.25M | -$2.15M | -$2.82M | -$4.12M |
| EPS (diluted) | -$0.62 | -$1.23 | -$1.89 | -$2.15 | -$3.45 | -$5.21 |